Recruiting T Cells and Sensitizing Tumors to NKG2D Immune Surveillance for Robust Antitumor Immune Response.

Xiang Li,Xuemeng Guo,Jiaxin Huang,Qing Lin,Bing Qin,Mengshi Jiang,Xinyu Shan,Zhenyu Luo,Junlei Zhang,Yingying Shi,Yichao Lu,Xu Liu,Yongzhong Du,Fuchun Yang,Lihua Luo,Jian You

DOI: https://doi.org/10.1016/j.jconrel.2022.12.032

IF: 11.467

2022-01-01

Journal of Controlled Release

Abstract:Although recruiting T cells to convert cold tumors into hot can prevent some tumors from evading immune surveillance, tumors have evolved more mechanisms to achieve immune evasion, such as downregulating major histocompatibility complex I (MHC I) molecules expression to prevent T cells from recognizing tumor-antigens, or secreting immune suppression cytokines that disable T cells. Tumor immune evasion not only promotes tumor growth, but also weakens the efficacy of existing tumor immunotherapies. Therefore, recruiting T cells while reshaping innate immunity plays an important role in preventing tumor immune escape. In this study, we constructed a long-acting in situ forming implant (ISFI) based on the Atrigel technology, co-encapsulated with G3-C12 and sulfisoxazole (SFX) as a drug depot in the tumor site (SFX + G3-C12-ISFI). First, G3-C12 could recruit T cells, and transform cold into hot tumors. Furthermore, SFX could inhibit tumor-derived exosomes secretion, reduce the shedding of NKG2D ligand (NKG2DL), repair NKG2D/NKG2DL pathway, reinvigorate natural killer (NK) cells, and evade the effects of MHC I molecules missing. In the humanized cold tumor model, our strategy showed an excellent anti-tumor effect, providing a smart strategy for solving tumor evasion immune surveillance.